Lataa...
Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study
BACKGROUND: Combination of the inhaled long-acting muscarinic antagonist umeclidinium (UMEC; GSK573719) with the long-acting β(2)-agonist vilanterol (VI) is an approved maintenance treatment for COPD in the US and EU. We compared the efficacy and safety of UMEC/VI with placebo in patients with COPD...
Tallennettuna:
| Julkaisussa: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4562726/ https://ncbi.nlm.nih.gov/pubmed/26366068 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S81053 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|